BackNKGen Biotech- Warrants (01/09/2028) Overview
NKGen Biotech Inc - Warrants (01/09/2028)

NKGen Biotech- Warrants (01/09/2028) Return on Equity

Latest ROE for NKGen Biotech- Warrants (01/09/2028): 46.8% — see history and peer comparisons.

Get informed when a big investor buys or sells

+ Follow

ROE

46.80%

Return on Equity

46.80%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

NKGen Biotech- Warrants (01/09/2028) (NKGNW) FAQ

The latest ROE for NKGNW is 46.8%. That is above the sector sector average of -5.87%. Investors often review this figure alongside NKGen Biotech- Warrants (01/09/2028)'s historical trend and sector peers before judging valuation or financial health.

Against its sector companies, NKGNW currently prints 46.8% for ROE, while the sector average sits near -5.87%. That is roughly 897.4% above the sector mean. Large gaps often invite a closer look at NKGen Biotech- Warrants (01/09/2028)'s growth, margins, and balance sheet.

Return on Equity shows how effectively NKGen Biotech- Warrants (01/09/2028) converts resources into returns. At 46.8%, NKGNW may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting NKGNW's ROE (46.8%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.